BioMark Diagnostics Inc. (BMKDF)
USD 0.18
(-5.26%)
USD 0.18
(-5.26%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 454.15 Thousand CAD | 0.0% |
| 2023 | 217.41 Thousand CAD | -64.12% |
| 2022 | 606.03 Thousand CAD | 452.87% |
| 2021 | 109.61 Thousand CAD | 0.0% |
| 2020 | - CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 546.51 Thousand CAD | 0.0% |
| 2024 Q1 | 182.36 Thousand CAD | 0.0% |
| 2024 Q2 | 145.95 Thousand CAD | 0.0% |
| 2024 Q4 | 454.15 Thousand CAD | 0.0% |
| 2024 FY | 454.15 Thousand CAD | 108.89% |
| 2023 FY | 217.41 Thousand CAD | -64.12% |
| 2023 Q3 | 346.28 Thousand CAD | -17.65% |
| 2023 Q4 | 217.41 Thousand CAD | -37.22% |
| 2023 Q2 | 420.48 Thousand CAD | -17.32% |
| 2023 Q1 | 508.59 Thousand CAD | -16.08% |
| 2022 Q3 | 678.61 Thousand CAD | 537.75% |
| 2022 Q1 | 108.01 Thousand CAD | -1.46% |
| 2022 FY | 606.03 Thousand CAD | 452.87% |
| 2022 Q4 | 606.03 Thousand CAD | -10.7% |
| 2022 Q2 | 106.4 Thousand CAD | -1.49% |
| 2021 Q4 | 109.61 Thousand CAD | 9.62% |
| 2021 FY | 109.61 Thousand CAD | 0.0% |
| 2021 Q1 | - CAD | 0.0% |
| 2021 Q3 | 100 Thousand CAD | 25.0% |
| 2021 Q2 | 80 Thousand CAD | 0.0% |
| 2020 FY | - CAD | 0.0% |
| 2020 Q4 | - CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 Q2 | - CAD | 0.0% |
| 2020 Q1 | - CAD | 0.0% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 6000.00 USD | -7469.267% |
| Arrayit Corporation | - USD | -Infinity% |
| Atlantic International Corp. | 1.29 Million USD | 64.998% |
| Biocept, Inc. | 10.37 Million USD | 95.623% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 51.3 Million USD | 99.115% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 61.22 Million USD | 99.258% |
| HTG Molecular Diagnostics, Inc. | 546.32 Thousand USD | 16.871% |
| iMD Companies, Inc. | 1.1 Million USD | 58.85% |
| IDenta Corp. | 428.17 Thousand USD | -6.068% |
| Interpace Biosciences, Inc. | 4.24 Million USD | 89.296% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | - USD | -Infinity% |
| Lumos Diagnostics Holdings Limited | - USD | -Infinity% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 278 Thousand USD | -63.365% |
| NovelStem International Corp. | 3.32 Million USD | 86.34% |
| Optigenex Inc. | 4.42 Million USD | 89.741% |
| PharmChem, Inc. | - USD | -Infinity% |
| Proteome Sciences plc | 1.63 Million USD | 72.155% |
| Response Genetics, Inc | 4.91 Million USD | 90.765% |
| Rennova Health, Inc. | 359.19 Thousand USD | -26.438% |
| RushNet, Inc. | 4.25 Million USD | 89.32% |
| ScreenPro Security Inc. | 249.05 Thousand USD | -82.355% |
| Stella Diagnostics Inc. | 798.44 Thousand USD | 43.12% |
| StageZero Life Sciences Ltd. | 576.38 Thousand USD | 21.206% |
| Todos Medical Ltd. | 33 Million USD | 98.624% |